Page 12 - Bryan Dunn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, 1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S. Helps protect against more serotypes of pneumococcal disease than any other conjugate vaccine Builds on Pfizer’s more than 20-year legacy and innovation in ...

LENOX — Two business partners who recently purchased the historic Church Street Inn for $2.6 million have added two more downtown bed-and-breakfasts to their portfolio for a total downtown Lenox lodging industry investment of $5.5 million in March. Seth Johnson and Russell Lange spent a combined $2.9 million for the Birchwood Inn on Hubbard Street, across from the Church on the Hill just north of the business district, and for the Rookwood Inn on Old Stockbridge Road, adjacent to Town Hall. The two latest real estate transactions were recorded March 30 at the Berkshire Middle Registry of...

Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis Pfizer Inc. today announced that the U.S. Food and Drug Administration has extended the priority review period for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis. The Prescription Drug User Fee Act goal date has been extended three months to early Q3 2021. The FDA has also extended the review period for the Supplemental New Drug … Pfizer Inc. (NYSE: PFE) today announced that the...

Pfizer Forward-Looking Statements The information contained in this release is as of March 8, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.  This release contains forward-looking information about a Lyme disease vaccine candidate, VLA15, and a collaboration between Pfizer and Valneva for VLA15, including their potential benefits and a potential phase 3 start, that involves substantial risks and uncertainties that could cause actual results to differ materially from those ex...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate VALNEVAMarch 8, 2021 GMT The Phase 2 study will include both adult and pediatric subjects with an aim to support acceleration of the vaccine candidate’s pediatric program   VLA15 will be  tested at two different schedules (Month 0-2-6 or Month 0-6) receiving the selected dose of 180µg VLA15 is the only Lyme disease vaccine candidate in active clinical development Saint-Herblain (France) and New York, NY, ...